Project Grant R01CA296285
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$482K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at overcoming rapid resistance to targeted therapies in colorectal cancer. The key products and services to be delivered under this 2-year award include: Evaluating how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer through analysis of...
The National Cancer Institute (NCI) awarded a $154,642 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Targeting the Evolving Immunopeptidome of Metastatic Colorectal Cancer," aims to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic lesion patient-derived organoids (PDOs) through mass spectrometry. This will identify conserved...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory provides $640,583 to enhance the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their metabolic fitness and anti-tumor activity within the tumor microenvironment. The research aims to delineate the mechanisms by which PPARD activation improves CD8+ T cell...
The National Cancer Institute (NCI) awarded a $162,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund research focused on "Targeting the HER Family in KRAS Mutant Colorectal Cancer." The research aims to determine the efficacy of co-targeting HER3 and KRAS in KRAS mutant colorectal cancer cell lines and patient-derived xenografts, as well as delineate the adaptive...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...
This $698,456.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports the "Development of a Universal mRNA Vaccine Targeting APC Mutations for Colorectal Cancer Prevention" at the Sloan-Kettering Institute for Cancer Research in New York, NY. The three-year award, running from November 1, 2024 to October 31, 2027, will fund innovative research to develop a novel mRNA-based vaccine targeting...
The National Cancer Institute (NCI) awarded a $235,710 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to Yale University. The grant, effective September 1, 2024 through March 31, 2027, aims to develop improved diagnostic approaches for assessing HER2 expression in breast cancer patients to enable more accurate selection of trastuzumab deruxtecan (T-DXD) therapy. The proposal has two key objectives: 1) Quantify spatial heterogeneity and HER2 expression...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611.00 to the University of Texas Health Science Center at Houston to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives are to: Characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived organoids. Develop and evaluate highly potent GPR56-targeted...
This $181,640 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research led by a clinical scientist at The University of Texas MD Anderson Cancer Center. The primary objectives are to: Expand on the role of liquid biopsy biomarkers, specifically circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA), to generate novel combination immunotherapy trials for colorectal and anal cancers. This includes analyzing samples from...